On Friday, the Kaiser Health Network (KHN) unveiled “Pre$cription for Power,” a database of 12,000 donations from large pharmaceutical companies to US patient advocacy groups. KHN has done everyone a favor by making this information easily accessible. In addition, it has reminded us of the importance of disclosure at a time when confidence in the […]
Read the Full ArticleIncreased focus on patient perspective over the past few years has resulted in a flood of new firms pitching their ability to do work in this area. Just because someone says they do patient engagement, however, doesn’t mean they have the expertise to do it well. Effective patient engagement is relational rather than transactional, transparent […]
Read the Full ArticleCategories:
Patient Advocate, Patient Centricity, Patient Engagement, Priority partners, R&D, Rare Disease, Strategy, ValueI along with 79% of American adults, per a 2016 PEW Research Center study, have a private Facebook account. One day, I browsed my news feed and saw someone ask in a Facebook group, “Does anyone know anyone or is on immunotherapy that recommends the most effective [sic] for lung cancer?” I was surprised on […]
Read the Full ArticleI remember going to the Annual Society of Clinical Oncology (ASCO) meeting ten years ago and lung cancer was hardly even being addressed even though it has the highest mortality rate – higher than breast cancer, colon cancer and prostate cancer combined. This year was quite different. Lung cancer was being discussed everywhere including the […]
Read the Full ArticleCategories:
Innovation, Patient Advocate, Patient Centricity, Patient Engagement, Patient Journey Mapping, R&DA Closer Look at the Crohn’s & Colitis Foundation’s Newest Initiative: The Clinical Trial Community Clinical trial recruitment is often one of the most challenging steps in the approval process for new treatments. For inflammatory bowel disease (IBD) patients suffering from Crohn’s disease or ulcerative colitis, new treatment options are often the “game changer” they […]
Read the Full ArticleThere’s a lot of buzz these days about Precision Medicine, the Moonshot, new targeted therapies and immunotherapies but one thing has not changed…. a cancer treatment’s efficacy and safety must be tested in a clinical trial. Historically only 3-5% of adult cancer patients participate in clinical trials. Genomic medicine creates even more challenges for the […]
Read the Full ArticleCategories:
Early Engagement, Patient Advocate, Patient Centricity, Patient Engagement, R&D, StrategyInsights from this year’s European Conference on Rare Diseases and Orphan Products (ECRD) reinforce the necessity of fostering trust in collaborations between industry and patient groups. At the same time, they point to barriers that prevent the development of this essential component of successful partnerships. In a panel chaired by Mark Krueger, MPH, MK&A’s president, […]
Read the Full ArticleOn October 26th and 27th at the Better Science, Better Health: New Healthcare Models meeting in Washington D.C., European and American health care leaders met in the US Congress to consider how new scientific breakthroughs such as targeted therapies, big data, and precision medicine will change drug development, approval and use. A consistent theme was […]
Read the Full ArticleRecently my mother, a retired registered nurse, told me something she was taught in nursing school which today most of us would find unsettling. Patients with terminal diseases, she was told, must not be informed of their illness. Only the families are to be notified, and it’s up to them to decide what, if anything, […]
Read the Full ArticleThis is the second in a two-part series about involving patients and advocacy groups in clinical trials. The first blog entry, can be found here: Patient advocate engagement in early stage development. Since 2010, MK&A and The Brooks Group have produced a syndicated market research report for the pharmaceutical industry to provide competitive benchmarking and […]
Read the Full ArticleTwice a year, MK&A associates attend an offsite meeting to plan, improve our skills and stay up-to-date on the latest in patient, professional and consumer trends and research. At our March meeting we invited a panel of advocates to discuss why and how their organizations are investing time and resources in the development process of […]
Read the Full Article